Drugs / Kamuvudine-9
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06781255 | Mar 2025 → Feb 2026 | diabetic macular edema | Michelle Abou-Jaoude | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT06467435 | Nov 2024 → Feb 2026 | disease of orbital part of eye adnexa | Peter Timoney | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kamuvudine-9 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06467435 ↗ |
| Action | Inhibit | “inflammasome inhibitor” NCT06781255 ↗ |
| Route | Oral | “Patients will receive oral K9 BID for up to 24 weeks” NCT06467435 ↗ |